Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Capital Expenditures: 2014-2024

Historic Capital Expenditures for Protagonist Therapeutics (PTGX) over the last 11 years, with Dec 2024 value amounting to $1.4 million.

  • Protagonist Therapeutics' Capital Expenditures fell 88.57% to $88,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 65.04%. This contributed to the annual value of $1.4 million for FY2024, which is 122.50% up from last year.
  • As of FY2024, Protagonist Therapeutics' Capital Expenditures stood at $1.4 million, which was up 122.50% from $609,000 recorded in FY2023.
  • Protagonist Therapeutics' Capital Expenditures' 5-year high stood at $1.4 million during FY2024, with a 5-year trough of $471,000 in FY2020.
  • Its 3-year average for Capital Expenditures is $919,667, with a median of $795,000 in 2022.
  • Its Capital Expenditures has fluctuated over the past 5 years, first crashed by 51.29% in 2020, then skyrocketed by 133.76% in 2021.
  • Over the past 5 years, Protagonist Therapeutics' Capital Expenditures (Yearly) stood at $471,000 in 2020, then soared by 133.76% to $1.1 million in 2021, then declined by 27.79% to $795,000 in 2022, then fell by 23.40% to $609,000 in 2023, then surged by 122.50% to $1.4 million in 2024.